Atorvastatin
- TRADE NAME: Lipitor (Pfizer)
- INDICATIONS: Hypercholesterolemia
- CLASS: HMG-CoA reductase inhibitor, Statin
- HALF-LIFE: 14 hours
Alcohol, Aliskiren, Amiodarone, Antifungals, Atazanavir, Azithromycin, Bexarotene, Boceprevir, Bosentan, Ciprofibrate, Clarithromycin, Clopidogrel, Colchicine, Conivaptan, Cyclosporine, CYP3A4 inhibitors, Danazol, Daptomycin, Dasatinib, Digoxin, Diltiazem, Dronedarone, Efavirenz, Eltrombopag, Erythromycin, Estradiol, Etravirine, Everolimus, Fenofibrate, Fenofibric acid, Fibrates, Fluconazole, Fosamprenavir, Fusidic Acid, Gemfibrozil, Grapefruit Juice, Imatinib, Imidazoles, Indinavir, Itraconazole, Liraglutide, Lopinavir, Macrolide antibiotics, Midazolam, Nefazodone, Nelfinavir, Niacin, Niacinamide, Norethisterone, Oral Contraceptives, P-glycoprotein inhibitors, Posaconazole, Protease inhibitors, Quinine, Red Rice Yeast, Rifampin, Ritonavir, Rivaroxaban, Saquinavir, Silodosin, St John's Wort, Telaprevir, Telithromycin, Tipranavir, Topotecan, Trabectedin, Verapamil, Warfarin
PREGNANCY CATEGORY: X
Safety and effectiveness in patients <10 years of age have not been established.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of atorvastatin in the Informa Healthcare journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life Threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric